Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency

Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency

Background. Influenza prophylaxis with the use of quadrivalent vaccines (QIV) is increasingly being introduced into healthcare practice. Methods. In total, 32 healthy adults and 6 patients with common variable immunodeficiency (CVID) received adjuvant QIV during 2018–2019 influenza season. Depending...

Full description

Bibliographic Details
Main Authors: Mikhail P. Kostinov, Elena A. Latysheva, Aristitsa M. Kostinova, Nelly K. Akhmatova, Tatyana V. Latysheva, Anna E. Vlasenko, Yulia A. Dagil, Ekaterina A. Khromova, Valentina B. Polichshuk
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Vaccines
Subjects:
adjuvanted QIV
immunogenicity
influenza
seropositive/seronegative
CVID
azoximer bromide
Online Access:https://www.mdpi.com/2076-393X/8/4/640

Internet

https://www.mdpi.com/2076-393X/8/4/640

Similar Items